PremiumThe FlyMira Pharmaceuticals announces new in vitro preclinical data on SKNY-1 MIRA Pharmaceuticals Reveals Promising SKNY-1 Preclinical Data Mira Pharmaceuticals announces Ketamir-2 manuscript accepted for publication PremiumCompany AnnouncementsMIRA Pharmaceuticals Appoints New Chief Financial Officer Psychedelic: Compass, GH Research, MindMed report quarterly earnings Mira Pharmaceuticals announces board approval of SKNY acquisition PremiumThe FlyMira Pharmaceuticals reports in vitro drug release data for topical Ketamir-2 Psychedelic: MindMed announces dosing in Phase 3 Emerge study Mira Pharmaceuticals announces results for Ketamir-2 in diabetic neuropathy